UniQure - Stock Price History | QURE
Historical daily share price chart and data for UniQure since 2023 adjusted for splits. The latest closing stock price for UniQure as of February 03, 2023 is 22.52.
- The all-time high UniQure stock closing price was 82.19 on June 21, 2019.
- The UniQure 52-week high stock price is 28.25, which is 25.4% above the current share price.
- The UniQure 52-week low stock price is 12.52, which is 44.4% below the current share price.
- The average UniQure stock price for the last 52 weeks is 19.31.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
| UniQure Historical Annual Stock Price Data |
| Year |
Average Stock Price |
Year Open |
Year High |
Year Low |
Year Close |
Annual % Change |
| 2022 |
19.0179 |
21.5000 |
27.3200 |
13.1500 |
22.6700 |
9.31% |
| 2021 |
32.0768 |
36.7600 |
42.0300 |
20.2400 |
20.7400 |
-42.60% |
| 2020 |
49.8212 |
70.2600 |
73.9700 |
35.3500 |
36.1300 |
-49.58% |
| 2019 |
55.3367 |
28.5300 |
82.1900 |
27.3900 |
71.6600 |
148.65% |
| 2018 |
29.7859 |
20.1600 |
43.0800 |
17.1000 |
28.8200 |
47.12% |
| 2017 |
8.6833 |
5.8700 |
19.5900 |
4.8200 |
19.5900 |
249.82% |
| 2016 |
10.3052 |
15.8100 |
18.2300 |
5.6000 |
5.6000 |
-66.14% |
| 2015 |
23.7932 |
14.7100 |
33.6300 |
14.7100 |
16.5400 |
11.68% |
| 2014 |
12.1273 |
14.6100 |
18.0500 |
8.6300 |
14.8100 |
0.00% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$1.054B |
$0.524B |
|
UNIQURE B.V. is involved in developing gene therapy for patients of genetic or acquired diseases. It offers Glybera for the treatment of lipoprotein lipase deficiency, an orphan metabolic disease. The company's product pipeline includes which are in clinical trials are additional adeno-associated virus consist of AMT-060, AMT-021, AMT-110 and AAV2/glial. UNIQURE B.V. is headquartered in Amsterdam, the Netherlands.
|
